Please use this identifier to cite or link to this item:
|Title:||Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation||Authors:||Ng, S.K.L.
|Issue Date:||18-Sep-2009||Citation:||Ng, S.K.L., Neo, S.-Y., Yap, Y.-W., Karuturi, R.K.M., Loh, E.S.L., Liau, K.-H., Ren, E.-C. (2009-09-18). Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation. Biochemical and Biophysical Research Communications 387 (2) : 310-315. ScholarBank@NUS Repository. https://doi.org/10.1016/j.bbrc.2009.07.013||Abstract:||Cancer such as hepatocellular carcinoma (HCC) is characterized by complex perturbations in multiple signaling pathways, including the phosphoinositide-3-kinase (PI3K/AKT) pathways. Herein we investigated the role of PI3K catalytic isoforms, particularly class II isoforms in HCC proliferation. Among the siRNAs tested against the eight known catalytic PI3K isoforms, specific ablation of class II PI3K alpha (PIK3C2α) was the most effective in impairing cell growth and this was accompanied by concomitant decrease in PIK3C2α mRNA and protein levels. Colony formation ability of cells deficient for PIK3C2α was markedly reduced and growth arrest was associated with increased caspase 3 levels. A small but significant difference in gene dosage and expression levels was detected between tumor and non-tumor tissues in a cohort of 19 HCC patients. Taken together, these data suggest for the first time that in addition to class I PI3Ks in cancer, class II PIK3C2α can modulate HCC cell growth. © 2009 Elsevier Inc. All rights reserved.||Source Title:||Biochemical and Biophysical Research Communications||URI:||http://scholarbank.nus.edu.sg/handle/10635/120842||ISSN:||0006291X||DOI:||10.1016/j.bbrc.2009.07.013|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jun 18, 2019
WEB OF SCIENCETM
checked on Jun 10, 2019
checked on May 25, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.